Revvity (RVTY) Stock Price

Revvity Price

NYSE·CLOSED
112.00USD
Market closed

Over the last 19 years Revvity grew revenue by 3.4% annually, reaching 2.86 B USD. Earnings per share have grown at 4.2% per year over the last 19 years. For Revvity, the net margin of 8.4% is down versus 24.6% a few years ago. At today's price the dividend yield works out to roughly 0.25%. The payout ratio is around 14% of earnings.

Revvity stock price

Volume
Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Revvity over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Revvity stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Revvity's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Revvity Stock Price History
DateRevvity Price
Access this data via the Eulerpool API

Revvity Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
1.51 B USD
148.4 M USD
119.6 M USD
Jan 1, 2007
1.73 B USD
166.4 M USD
131.7 M USD
Jan 1, 2008
1.66 B USD
154.3 M USD
122.2 M USD
Jan 1, 2009
1.55 B USD
133.9 M USD
82.1 M USD
Jan 1, 2010
1.7 B USD
179.4 M USD
391 M USD
Jan 1, 2011
1.92 B USD
118.8 M USD
7.7 M USD
Jan 1, 2012
2.11 B USD
202.3 M USD
69.9 M USD
Jan 1, 2013
2.16 B USD
261.9 M USD
167.2 M USD
Jan 1, 2014
2.24 B USD
224.1 M USD
157.8 M USD
Jan 1, 2015
2.1 B USD
264.4 M USD
212.4 M USD
Jan 1, 2016
2.12 B USD
299.7 M USD
234.3 M USD
Jan 1, 2017
2.26 B USD
308.3 M USD
292.6 M USD
Jan 1, 2018
2.78 B USD
335 M USD
237.9 M USD
Jan 1, 2019
2.88 B USD
398 M USD
227.6 M USD
Jan 1, 2020
3.78 B USD
1.01 B USD
727.9 M USD

Revvity Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 7, 2026, 5:22 AM
 
REVENUE (B USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B USD)
NET INCOME (B USD)
NET INCOME GROWTH (%)
DIV. (USD)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
202420252026e2027e2028e2029e2030e2031e
2.762.863.043.193.373.623.864.39
0.183.676.345.15.677.416.4613.74
55.7954.7651.54946.3743.1740.5535.65
1.541.561.561.561.561.561.561.56
0.270.240.620.690.760.850.951.14
-61.04-10.74158.5110.9110.1311.711.1820.11
0.280.280.140.750.81---
-50435.718
122.82116.6116.6116.6116.6116.6116.6116.6
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Revvity generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Revvity retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Revvity's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Revvity has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Revvity's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Revvity stock margins

The Revvity margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Revvity. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Revvity.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
54.77 %
9.84 %
7.93 %
Jan 1, 2007
41.21 %
9.62 %
7.62 %
Jan 1, 2008
44.21 %
9.3 %
7.36 %
Jan 1, 2009
45.22 %
8.63 %
5.29 %
Jan 1, 2010
44.58 %
10.54 %
22.98 %
Jan 1, 2011
44.19 %
6.19 %
0.4 %
Jan 1, 2012
45.67 %
9.61 %
3.32 %
Jan 1, 2013
45.24 %
12.14 %
7.75 %
Jan 1, 2014
44.9 %
10.02 %
7.05 %
Jan 1, 2015
45.81 %
12.56 %
10.09 %
Jan 1, 2016
47.95 %
14.17 %
11.08 %
Jan 1, 2017
47.58 %
13.66 %
12.96 %
Jan 1, 2018
48.27 %
12.06 %
8.56 %
Jan 1, 2019
48.41 %
13.8 %
7.89 %
Jan 1, 2020
55.78 %
26.65 %
19.24 %

Revvity Stock Revenue, EBIT, Earnings per Share

The Revvity earnings per share therefore indicates how much revenue Revvity has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
11.93 USD
1.17 USD
0.95 USD
Jan 1, 2007
14.34 USD
1.38 USD
1.09 USD
Jan 1, 2008
13.98 USD
1.3 USD
1.03 USD
Jan 1, 2009
13.3 USD
1.15 USD
0.7 USD
Jan 1, 2010
14.42 USD
1.52 USD
3.31 USD
Jan 1, 2011
16.84 USD
1.04 USD
0.07 USD
Jan 1, 2012
18.32 USD
1.76 USD
0.61 USD
Jan 1, 2013
19.01 USD
2.31 USD
1.47 USD
Jan 1, 2014
19.68 USD
1.97 USD
1.39 USD
Jan 1, 2015
18.58 USD
2.33 USD
1.87 USD
Jan 1, 2016
19.18 USD
2.72 USD
2.12 USD
Jan 1, 2017
20.35 USD
2.78 USD
2.64 USD
Jan 1, 2018
24.91 USD
3 USD
2.13 USD
Jan 1, 2019
26.03 USD
3.59 USD
2.05 USD
Jan 1, 2020
33.74 USD
8.99 USD
6.49 USD

Revvity business model & stock analysis

PerkinElmer Inc is an international company headquartered in Waltham, Massachusetts, USA. It provides solutions for improving health and the environment by offering instruments, consumables, software, and services in multiple industries. The company's history began in 1937 when Perkin-Elmer (named after two partners) was founded. It initially focused on manufacturing spectrometers and other instruments for chemical analysis. During World War II, Perkin-Elmer dramatically shifted its business towards the development of rocket sighting devices and aircraft parts. After the war, it returned to producing scientific equipment and began expanding into other markets. In the 1960s, Perkin-Elmer entered the field of medical diagnostics and started developing solutions for measuring hormones and proteins. Over the following decades, the company grew through expansion and acquisitions, including the purchase of Applied Biosystems, in areas such as molecular diagnostics, chromatography, genomics, and environmental analytics. PerkinElmer's business model focuses on providing solutions for customers in various fields such as pharma and biotechnology, environment and food, diagnostics, and clinical research. This includes instruments and consumables for analyzing proteins, nucleic acids, and other chemical substances, molecular diagnostic instruments and software, imaging systems for drug screening, and computer platforms for processing large amounts of data. The offered products and services of PerkinElmer encompass a wide range of solutions. The company's chromatography division offers instruments and consumables for the separation and analysis of chemical compounds. The Environmental Health division provides solutions for the identification and monitoring of pollutants in the environment, as well as for investigating food and drugs. The Analytical Sciences service division offers a wide range of analytical services to assist customers in solving research and development challenges. Other products and services of PerkinElmer include solutions for genomic analysis, drug development and manufacturing, diagnostic systems, laboratory automation, as well as software and services for data management. PerkinElmer is also a major provider of instruments and services in the field of medical imaging. One of PerkinElmer's standout products is its solutions for DNA and RNA sequencing. Using these technologies, researchers can identify genetic information that is crucial for disease diagnosis and treatment, as well as the development of new therapies and drugs. Overall, PerkinElmer offers a broad range of offerings aimed at improving health, the environment, and quality of life. The company works closely with customers in various industries to tailor its offerings to their needs. PerkinElmer is a key provider of solutions for improving health and the environment. The company offers a wide range of products and services, including instruments and consumables for chromatography, solutions for genomic analysis, and imaging systems for drug screening. Through its close collaboration with customers in various industries, PerkinElmer uses its knowledge and technology to make the world a better place.

Revvity SWOT Analysis

Strengths

1. Strong market presence: PerkinElmer Inc has established itself as a leading player in the scientific research and diagnostics sector, with a wide range of products and services.

2. Technological expertise: The company possesses advanced technologies and innovative solutions, giving it a competitive edge in the market.

3. Diversified product portfolio: PerkinElmer offers a diverse range of products across various segments, including life sciences, diagnostics, environmental testing, and food safety.

Weaknesses

1. Dependence on key customers: PerkinElmer relies heavily on a few large customers for a significant portion of its revenue, which exposes it to potential risks if any of these customers reduce their business or switch to competitors.

2. High research and development costs: Developing and maintaining advanced technologies requires substantial investments, which may strain the company's financial resources.

Opportunities

1. Growing demand for diagnostics: The increasing prevalence of diseases and the need for early detection and accurate diagnosis provide a significant growth opportunity for PerkinElmer in the diagnostics market.

2. Expansion in emerging markets: PerkinElmer can explore untapped markets in developing countries, leveraging its expertise to cater to the rising demand for scientific research and diagnostics solutions.

3. Acquisitions and partnerships: Strategic acquisitions or partnerships with complementary companies can help PerkinElmer expand its product offerings and broaden its customer base.

Threats

1. Intense competition: The scientific research and diagnostics market is highly competitive, with numerous established players and new entrants. PerkinElmer must continually innovate to stay ahead.

2. Regulatory challenges: Changes in regulations and compliance requirements can affect the company's operations, potentially leading to increased costs or barriers to market entry.

3. Economic downturns: Global economic uncertainties and recessions can impact the demand for PerkinElmer's products and services, as customers may reduce spending on research and diagnostics.

Revvity Eulerpool Fair Value

Revvity historical P/E ratio, EBIT multiple, and P/S ratio

Revvity annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Revvity shares outstanding

The number of shares was Revvity in 2025 — This indicates how many shares 116.595 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
126.5 M base_Shares
Jan 1, 2007
120.6 M base_Shares
Jan 1, 2008
118.7 M base_Shares
Jan 1, 2009
116.6 M base_Shares
Jan 1, 2010
118 M base_Shares
Jan 1, 2011
113.9 M base_Shares
Jan 1, 2012
114.9 M base_Shares
Jan 1, 2013
113.5 M base_Shares
Jan 1, 2014
113.7 M base_Shares
Jan 1, 2015
113.3 M base_Shares
Jan 1, 2016
110.3 M base_Shares
Jan 1, 2017
110.9 M base_Shares
Jan 1, 2018
111.5 M base_Shares
Jan 1, 2019
110.8 M base_Shares
Jan 1, 2020
112.1 M base_Shares

Revvity Dividend History

37 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.14USDYTD
Jan 16, 20260.07USD 0.0%1/2
Apr 17, 20260.07USD 0.0%2/2
20250.28USD 0.0%
Jan 17, 20250.07USD 0.0%1/4
Apr 17, 20250.07USD 0.0%2/4
Jul 18, 20250.07USD 0.0%3/4
Oct 17, 20250.07USD 0.0%4/4
20240.28USD 0.0%
20230.28USD 0.0%
20220.28USD 0.0%
20210.28USD 0.0%
20200.28USD 0.0%
20190.28USD 0.0%
20180.28USD 0.0%
20170.28USD 0.0%

Revvity dividend history and estimates

In 2025, Revvity paid a dividend amounting to 0.28 USD. Dividend means that Revvity distributes a portion of its profits to its owners.
  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Invalid Date
0.28 USD
0 USD
Jan 1, 2007
0.28 USD
0 USD
Jan 1, 2008
0.28 USD
0 USD
Jan 1, 2009
0.28 USD
0 USD
Jan 1, 2010
0.28 USD
0 USD
Jan 1, 2011
0.28 USD
0 USD
Jan 1, 2012
0.28 USD
0 USD
Jan 1, 2013
0.28 USD
0 USD
Jan 1, 2014
0.28 USD
0 USD
Jan 1, 2015
0.28 USD
0 USD
Jan 1, 2016
0.28 USD
0 USD
Jan 1, 2017
0.28 USD
0 USD
Jan 1, 2018
0.28 USD
0 USD
Jan 1, 2019
0.28 USD
0 USD
Jan 1, 2020
0.28 USD
0 USD

Revvity dividend payout ratio

In 2025, Revvity had a payout ratio of 13.61%. The payout ratio indicates the percentage of the company's profits that Revvity distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
30.11 %
Jan 1, 2007
25.45 %
Jan 1, 2008
27.45 %
Jan 1, 2009
40 %
Jan 1, 2010
8.46 %
Jan 1, 2011
466.67 %
Jan 1, 2012
45.16 %
Jan 1, 2013
19.05 %
Jan 1, 2014
20.29 %
Jan 1, 2015
14.97 %
Jan 1, 2016
13.21 %
Jan 1, 2017
10.65 %
Jan 1, 2018
13.15 %
Jan 1, 2019
13.66 %
Jan 1, 2020
4.31 %
Price targets and forecasts for Revvity are not yet available.

Revvity Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/5/20261.04USD717.86 MUSD2026 Q1
4/27/20261.04USD716.89 MUSD2026 Q1
2/2/20261.58USD776.64 MUSD2025 Q4
1/29/20261.58USD776.64 MUSD2025 Q4
5/9/20241.04USD660.53 MUSD2024 Q1
2/12/20241.17USD683.14 MUSD2023 Q4

EESG©

Eulerpool ESG Scorecard© for the Revvity stock

88/100
99
Environment
99
Social
67
Governance
E

Environment

20
Scope 1 - Direct Emissions2,121
Scope 2 - Indirect emissions from purchased energy29,581
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions31,702
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees47
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Revvity shareholder structure

% Name
19.96993%
T. Rowe Price Investment Management, Inc.
T. Rowe Price Investment Management, Inc.
12.37557%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
6.87991%
T. Rowe Price Associates, Inc.
T. Rowe Price Associates, Inc.
6.36948%
Janus Henderson Investors
Janus Henderson Investors
5.98841%
EdgePoint Investment Group Inc.
EdgePoint Investment Group Inc.
5.12238%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
...

Revvity Executives and Management Board

PS

Dr. Prahlad Singh

(60)

President, Chief Executive Officer, Director · since 2016

Compensation11.93 M USD
JG

Mr. Joel Goldberg

(56)

Senior Vice President - Administration, General Counsel, Secretary

Compensation3.38 M USD
MK

Mr. Maxwell Krakowiak

(35)

Chief Financial Officer, Senior Vice President

Compensation3.25 M USD
MV

Ms. Miriame Victor

(44)

Chief Commercial Officer, Senior Vice President

Compensation2.48 M USD
TV

Mr. Tajinder Vohra

(59)

Senior Vice President - Global Operations

Compensation2.31 M USD

Frequently asked questions about Revvity

PerkinElmer Inc. is a company that focuses on providing products and services in the fields of diagnostics, life sciences, and applied services. Their business model revolves around offering innovative solutions for the healthcare and scientific community. With a wide range of product offerings, including instruments, reagents, consumables, software, and services, PerkinElmer Inc. aims to support scientific research, drug discovery, and diagnostics. By leveraging their expertise in detecting and analyzing biological and environmental challenges, the company strives to enable its customers to improve human and environmental health. PerkinElmer Inc.'s commitment to delivering advanced solutions makes it a trusted partner in the life sciences industry.

All fundamentals and in-depth analysis of Revvity

Our stock analysis for Revvity Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Revvity Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.